Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone 40 mg qd and Evaluating Genetic Biomarkers Associated With Treatment Response in Patients With Major Depressive Disorder (MDD).

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone 40 mg qd and Evaluating Genetic Biomarkers Associated With Treatment Response in Patients With Major Depressive Disorder (MDD).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilazodone (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Forest Laboratories

Most Recent Events

  • 30 Mar 2018 Results (n=2218) of post-hoc analysis of four randomized trials assessing efficacy in subgroups of patients with major depressive disorder, were published in the International Clinical Psychopharmacology.
  • 09 Oct 2013 Pooled post-hoc analysis assessing sustained response presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
  • 09 Oct 2013 Pooled post-hoc analysis assessing the effects of treatment on anxiety outcomes presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top